Cipla Q4 Results FY26: Net Profit Falls 54.6% to Rs 554.64 Crore on Impairment Charge, Revenue Down 2.8%, Dividend Rs 13 Per Share

Cipla Q4 results for the quarter ended March 31, 2026 show consolidated net profit declining 54.6 percent year-on-year to Rs 554.64 crore, weighed down by an impairment charge of Rs 42.02 crore taken in respect of associates due to changes in business conditions and market dynamics. Consolidated revenue from operations fell 2.8 percent year-on-year to Rs 6,541.20 crore. EBITDA margin contracted sharply to 14.6 percent from the 23 percent reported in the year-ago quarter. Despite the weak headline numbers, Cipla shares rose 3.7 percent to Rs 1,340.70 on the NSE following the results announcement, reflecting market relief that the decline was driven by a one-off charge rather than structural business deterioration.

Critically, Cipla management clarified that excluding the impairment charge, EBITDA for Q4 FY26 would have stood at Rs 997 crore with an EBITDA margin of 15.2 percent, which is closer to normalised operating performance. The board declared a final dividend of Rs 13 per equity share, with June 5, 2026 as the record date.

Click Here – Get Free Investment Predictions

Cipla Q4 FY26 Results: Key Financial Highlights

• Q4 FY26 Consolidated Net Profit: Rs 554.64 crore (down 54.6% YoY)
• Q4 FY26 Revenue from Operations: Rs 6,541.20 crore (down 2.8% YoY)
• Q4 FY26 EBITDA Margin (Reported): 14.6% (vs approximately 23% in Q4 FY25)
• Q4 FY26 EBITDA (Excluding Impairment): Rs 997 crore with margin of 15.2%
• Impairment Charge: Rs 42.02 crore (in respect of associates due to changes in business conditions and market dynamics)
• Final Dividend: Rs 13 per equity share
• Dividend Record Date: June 5, 2026
• CMP Post Results (13 May 2026): Rs 1,324.20 (rose 3.7% intraday to Rs 1,340.70 post results)
• 52-Week High: Rs 1,673
• 52-Week Low: Rs 1,165.70
• Market Cap: Rs 1,04,389.75 crore

Track Cipla share price and Q4 result data live on the Check the Univest Screener for live data.

Why Cipla Q4 Profit Fell 55%: Dissecting the Impairment Charge

Rs 42.02 Crore Impairment: The Whole Story

Cipla’s management disclosed that the Rs 42.02 crore impairment charge in Q4 FY26 was recorded in respect of investments in associate companies due to changes in certain business conditions and market dynamics. This is a non-cash, non-recurring accounting charge that reduces reported net profit without impacting operating cash flows. The impairment reflects a write-down in the book value of Cipla’s stake in specific associate entities rather than any deterioration in its core pharmaceutical business.

This distinction is important for interpreting the Cipla Q4 results correctly. Excluding the impairment, Cipla’s EBITDA would have been Rs 997 crore at a 15.2 percent margin, which is meaningfully closer to the company’s medium-term operating range. The near doubling of the impairment’s profit impact relative to its Rs 42 crore stated value reflects the tax and accounting treatment of the charge through the P&L.

Revenue Down 2.8%: US Business Pressure

Cipla’s Q4 FY26 revenue decline of 2.8 percent to Rs 6,541.20 crore from Rs 6,728 crore in Q4 FY25 primarily reflects weakness in its US generics business. Analysts at Zee Business had projected a 40 percent PAT decline before the actual 54.6 percent fall, noting that US operations were expected to be the key pressure point. Cipla derives a significant portion of revenue from US generic drug launches, and any slowdown in new product approvals, pricing pressure from generic competition or inventory adjustments at US distributors directly impacts quarterly revenue.

Why Cipla Shares Rose 3.7% Despite the 55% Profit Fall

The 3.7 percent post-results rally in Cipla shares to Rs 1,340.70 reflects market relief that the Q4 FY26 miss was driven primarily by a one-time, non-cash impairment charge rather than a structural deterioration in the business. Investors who had factored in a 40 percent profit decline based on analyst previews saw the 54.6 percent fall as worse than expected on the surface but understood that the underlying operating EBITDA of Rs 997 crore was not dramatically below expectations once the one-off was stripped out.

Additionally, the Rs 13 per share final dividend and the June 5 record date provide a near-term income catalyst. At the current share price of approximately Rs 1,324, the Rs 13 dividend represents a dividend yield of approximately 0.98 percent for the quarter alone, which is notable for a large-cap pharma company.

Cipla FY26 Performance and Outlook

Cipla has experienced a challenging FY26 with sequential quarterly profit declines throughout the year. Q3 FY26 net profit had already fallen 56.97 percent year-on-year to Rs 675.80 crore, and Q4 FY26’s Rs 554.64 crore is the weakest quarterly profit in recent years. The company’s Nifty Pharma index weight of 8.7 percent means sustained underperformance carries index-level implications.

Cipla’s FY27 outlook hinges on a recovery in the US business through new product launches, the respiratory franchise maintaining its leadership in the domestic market and the resolution of the business conditions that necessitated the impairment charge. Cipla’s India branded prescription business, particularly its respiratory, anti-infective and consumer wellness portfolios, has historically provided a stable revenue base that partially offsets US generics volatility.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Cipla share price live price and pharma sector research!

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Conclusion

Cipla Q4 results for FY26 show a 54.6 percent net profit decline to Rs 554.64 crore, largely attributable to a Rs 42.02 crore non-cash impairment charge rather than core business deterioration. Excluding the impairment, EBITDA would have been Rs 997 crore at a 15.2 percent margin. Revenue declined 2.8 percent to Rs 6,541 crore. The Rs 13 per share final dividend (record date June 5, 2026) and the market’s 3.7 percent post-results share price rally signal investor interpretation of the miss as one-off rather than structural. FY27 recovery in US generics is the key re-rating catalyst to watch. Consult a SEBI-registered advisor before investing based on Cipla Q4 results.

FAQs on Cipla Q4 Results FY26

Why did Cipla Q4 profit fall 55%?

Ans. Cipla’s Q4 FY26 consolidated net profit fell 54.6 percent to Rs 554.64 crore primarily due to a Rs 42.02 crore impairment charge taken in respect of associate companies due to changes in business conditions and market dynamics. Revenue also declined 2.8 percent to Rs 6,541 crore. Excluding the impairment, EBITDA would have been Rs 997 crore at a 15.2 percent margin.

What dividend did Cipla declare with Q4 results?

Ans. Cipla’s board declared a final dividend of Rs 13 per equity share for FY26, subject to shareholder approval at the AGM. The record date for dividend eligibility is June 5, 2026. The dividend will be paid within 30 days from the AGM date.

Why did Cipla shares rise after the weak Q4 results?

Ans. Cipla shares rose 3.7 percent to Rs 1,340.70 after the Cipla Q4 results because the profit fall was driven by a one-time, non-cash impairment charge rather than structural business deterioration. The Rs 13 dividend announcement and the clarification that underlying EBITDA excluding impairment would have been Rs 997 crore at 15.2 percent margin reassured investors.